Geneva Capital Management LLC Has $22.14 Million Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Geneva Capital Management LLC trimmed its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 852,741 shares of the medical equipment provider’s stock after selling 12,525 shares during the period. Geneva Capital Management LLC’s holdings in BioLife Solutions were worth $22,137,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BLFS. D.A. Davidson & CO. increased its position in BioLife Solutions by 1.3% in the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock worth $1,069,000 after purchasing an additional 519 shares during the last quarter. Stifel Financial Corp increased its position in BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the last quarter. Smartleaf Asset Management LLC increased its position in BioLife Solutions by 27.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 950 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions in the 4th quarter worth about $26,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions in the 3rd quarter worth about $28,000. 93.24% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS opened at $26.25 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. The business’s 50-day simple moving average is $26.67 and its 200-day simple moving average is $25.48. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the prior year, the company earned ($0.21) EPS. As a group, equities research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Activity at BioLife Solutions

In related news, CFO Troy Wichterman sold 987 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,978 shares of company stock worth $322,724 in the last 90 days. 2.20% of the stock is owned by company insiders.

Analyst Ratings Changes

BLFS has been the topic of several research reports. KeyCorp upped their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright dropped their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Finally, TD Cowen increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.